Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Apitegromab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Apitegromab: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Ketosteril Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ketosteril: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Fluoride [18F] Thretide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Fluoride [18F] Thretide: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
6 min read
Atezolizumab Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atezolizumab, a antibody targeting PD-L1.
Latest Hotspot
8 min read
Benzyldodecyldimethylammonium bromide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Benzyldodecyldimethylammonium bromide: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Gentuximab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Gentuximab: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
6 min read
Avelumab Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Avelumab, a antibody targeting PD-L1.
Latest Hotspot
8 min read
Pimitespib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Pimitespib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Darinaparsin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Darinaparsin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
6 min read
Quavonlimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Quavonlimab, a antibody targeting PD-1.
Latest Hotspot
6 min read
Balstilimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Balstilimab, a antibody targeting PD-1.
Latest Hotspot
8 min read
Gemigliptin/Dapagliflozin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Gemigliptin/Dapagliflozin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.